Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
2005 ◽
Vol 100
(2)
◽
pp. 414-423
◽
2020 ◽
Vol 14
(Supplement_1)
◽
pp. S632-S633
2001 ◽
Vol 120
(5)
◽
pp. A213-A213
◽